InsidersTradesSigma
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Explore the complete record of transactions filed by Peterson Amy C., Vice-Président Exécutif du Développement. Director active across 2 companies, notably CytomX Therapeutics, Inc.. In total, 10 filings have been recorded. Split: 0 buy · 1 sell. Total volume traded: €8k. Activity tracked since 31 May 2021. The latest transaction was filed on 15 May 2025 (Retenue fiscale). Regulator: SEC (Form 4). All data is accessible without signup.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
10 of 10 declarations
Peterson Amy C. is Executive Vice President of Development. She has 10 filings in total, and, across the sampled recent filings from 2021-06-08 to 2025-05-16, buys are 0 EUR and sells are 7960 EUR. The recent filings concern Exelixis, INC. and CytomX Therapeutics, Inc., with notable amounts of 906166.7184514918 EUR on 2024-11-19 and 331224.0641928224 EUR on 2025-05-16 at Exelixis, INC., as well as 16517.40605561804 EUR and 7960.236247579825 EUR at CytomX Therapeutics, Inc.